Top

Published in:

01-12-2009 | Review Article

Does Effective Management of Sleep Disorders Reduce Depressive Symptoms and the Risk of Depression?

Author: Professor Dieter Riemann

Published in: Drugs | Special Issue 2/2009

Abstract

The link between co-morbid insomnia and depression has been demonstrated in numerous groups. Insomnia has been associated with: (1) an increased risk of developing subsequent depression; (2) an increased duration of established depression; and (3) relapse following treatment for depression. In addition, specific insomnia symptoms, such as nocturnal awakening with difficulty resuming sleep, are more strongly associated with depression than classic symptoms of insomnia. Participants of a workshop, held at the 6th annual meeting of The International Sleep Disorders Forum: The Art of Good Sleep in 2008, evaluated whether the effective management of sleep disorders could reduce both concurrent depressive symptoms and the risk of developing subsequent depression. Following the workshop, a targeted literature review was conducted. Initial evidence demonstrated that in patients with insomnia and co-morbid depression either pharmacological treatment of insomnia or psychological treatment in the form of cognitive behavioural therapy for insomnia improved both insomnia and depressive symptoms. Although these appeared to be promising treatment strategies, however, of the 27 identified treatment studies, only one large well-designed randomized controlled trial comparing the efficacy of eszopiclone plus fluoxetine with placebo plus fluoxetine demonstrated unequivocal evidence that improvements in insomnia symptoms conferred additive benefits on depressive outcomes. In addition, it was unclear whether any differences exist in efficacy between sedating versus non-sedating pharmacotherapies for insomnia in this patient group. Further studies of sufficient sample size and duration are needed to evaluate combinations of pharmacological (either sedating or non-sedating) and psychological interventions in co-morbid insomnia and depression. This article reviews the level of evidence, recommendations and areas of particular interest for further study and discussion arising from this workshop.

Tsuno N, Besset A, Ritchie K. Sleep and depression. J Clin Psychiatry 2005; 66: 1254–69PubMedCrossRef

Mendelson WB, Gillin JC, Wyatt RD. Human sleep and its disorders. New York: Plenum Press, 1977CrossRef

Pigeon WR, Perlis ML. Insomnia and depression: Birds of a feather? Int J Sleep Disorders 2007; 1: 82–91

Riemann D, Voderholzer U. Primary insomnia: a risk factor to develop depression? J Affect Disord 2003; 76: 255–9PubMedCrossRef

Breslau N, Roth T, Rosenthal L, et al. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996; 39: 411–8PubMedCrossRef

Buysse DJ, Angst J, Gamma A, et al. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 2008; 31: 473–80PubMed

Chang PP, Ford DE, Mead LA, et al. Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study. Am J Epidemiol 1997; 146: 105–14

Dryman A, Eaton WW. Affective symptoms associated with the onset of major depression in the community: findings from the US National Institute of Mental Health Epidemiologic Catchment Area Program. Acta Psychiatr Scand 1991; 84: 1–5PubMedCrossRef

Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989; 262: 1479–84CrossRef

10.

Hein S, Bonsignore M, Barkow K, et al. Lifetime depressive and somatic symptoms as preclinical markers of late-onset depression. [erratum appears in Eur Arch Psychiatry Clin Neurosci. 2003; 253: 110]. Eur Arch Psychiatry Clin Neurosci 2003; 253: 16–21

11.

Jansson-Frojmark M, Lindblom K. A bidirectional relationship between anxiety and depression, and insomnia? A prospective study in the general population. J Psychosom Res 2008; 64: 443–9PubMedCrossRef

12.

Mallon L, Broman JE, Hetta J. Relationship between insomnia, depression, and mortality: a 12-year follow-up of older adults in the community. Int Psychogeriatr 2000; 12: 295–306PubMedCrossRef

13.

Morphy H, Dunn KM, Lewis M, et al. Epidemiology of insomnia: a longitudinal study in a UK population. Sleep 2007; 30: 274–80PubMed

14.

Neckelmann D, Mykletun A, Dahl AA. Chronic insomnia as a risk factor for developing anxiety and depression. Sleep 2007; 30: 873–80PubMed

15.

Roberts RE, Shema SJ, Kaplan GA, et al. Sleep complaints and depression in an aging cohort: a prospective perspective. Am J Psychiatry 2000; 157: 81–8PubMed

16.

Vollrath M, Wicki W, Angst J. The Zurich study. VIII. Insomnia: association with depression, anxiety, somatic syndromes, and course of insomnia. Eur Arch Psychiatry Neurol Sci 1989; 239: 113–24

17.

Weissman MM, Greenwald S, Nino-Murcia G, et al. The morbidity of insomnia uncomplicated by psychiatric disorders. Gen Hosp Psychiatry 1997; 19: 245–50PubMedCrossRef

18.

Brabbins CJ, Dewey ME, Copeland JRM, et al. Insomnia in the elderly: prevalence, gender differences and relationships with morbidity and mortality. Int J Geriatr Psychiatry 1993; 8: 473–80CrossRef

19.

Foley DJ, Monjan A, Simonsick EM, et al. Incidence and remission of insomnia among elderly adults: an epide-miologic study of 6,800 persons over three years. Sleep 1999; 22 (Suppl. 2): S366–72PubMed

20.

Livingston G, Blizard B, Mann A. Does sleep disturbance predict depression in elderly people? A study in inner London [see comment]. Br J Gen Pract 1993; 43: 445–8PubMed

21.

Fava GA, Grandi S, Canestrari R, et al. Prodromal symptoms in primary major depressive disorder. J Affect Disord 1990; 19: 149–52PubMedCrossRef

22.

Perlis ML, Giles DE, Buysse DJ, et al. Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord 1997; 42: 209–12PubMedCrossRef

23.

Hidalgo JL, Gras CB, Garcia YD, et al. Functional status in the elderly with insomnia. Qual Life Res 2007; 16: 279–86PubMedCrossRef

24.

Almeida OP, Pfaff JJ. Sleep complaints among older general practice patients: association with depression. Br J Gen Pract 2005; 55: 864–6PubMed

25.

Kaneita Y, Ohida T, Uchiyama M, et al. The relationship between depression and sleep disturbances: a Japanese nationwide general population survey. J Clin Psychiatry 2006; 67: 196–203PubMedCrossRef

26.

Buckner JD, Bernert RA, Cromer KR, et al. Social anxiety and insomnia: the mediating role of depressive symptoms. Depress Anxiety 2008; 25: 124–30PubMedCrossRef

27.

Garvey MJ, Schaffer CB. Are some symptoms of depression age dependent? J Affect Disord 1994; 32: 247–51PubMedCrossRef

28.

Hidalgo MP, Caumo W. Sleep disturbances associated with minor psychiatric disorders in medical students. Neurol Sci 2002; 23: 35–9PubMedCrossRef

29.

Hohagen F, Rink K, Kappler C, et al. Prevalence and treatment of insomnia in general practice. A longitudinal study. Eur Arch Psychiatry Clin Neurosci 1993; 242: 329–36CrossRef

30.

Kawada T, Yosiaki S, Yasuo K, et al. Population study on the prevalence of insomnia and insomnia-related factors among Japanese women. Sleep Med 2003; 4: 563–7PubMedCrossRef

31.

Liljenberg B, Almwvist M, Hetta J, et al. Affective disturbance and insomnia: a population study. Eur J Psychiat 1989; 3: 91–8

32.

Ohayon MM, Caulet M, Lemoine P. Comorbidity of mental and insomnia disorders in the general population. Compr Psychiatry 1998; 39: 185–97PubMedCrossRef

33.

Schramm E, Hohagen F, Kappler C, et al. Mental comorbidity of chronic insomnia in general practice attenders using DSM-III-R. Acta Psychiatr Scand 1995; 91: 10–17PubMedCrossRef

34.

Spoormaker VI, van den Bout J. Depression and anxiety complaints; relations with sleep disturbances. Eur Psychiatry 2005; 20: 243–5PubMedCrossRef

35.

Stewart R, Besset A, Bebbington P, et al. Insomnia comorbidity and impact and hypnotic use by age group in a national survey population aged 16 to 74 years. Sleep 2006; 29: 1391–7PubMed

36.

Vandeputte M, de Weerd A. Sleep disorders and depressive feelings: a global survey with the Beck depression scale. Sleep Med 2003; 4: 343–5PubMedCrossRef

37.

Ohayon MM. Prevalence and correlates of nonrestorative sleep complaints. Arch Intern Med 2005; 165: 35–41PubMedCrossRef

38.

Bazargan M. Self-reported sleep disturbance among African-American elderly: the effects of depression, health status, exercise, and social support. Int J Aging Hum Dev 1996; 42: 143–60PubMedCrossRef

39.

Brown LF, Reynolds CF III, Monk TH, et al. Social rhythm stability following late-life spousal bereavement: associations with depression and sleep impairment. Psychiatry Res 1996; 62: 161–9PubMedCrossRef

40.

Froese CL, Butt A, Mulgrew A, et al. Depression and sleep-related symptoms in an adult, indigenous, North American population. J Clin Sleep Med 2008; 4: 356–61PubMed

41.

Hall M, Buysse DJ, Dew MA, et al. Intrusive thoughts and avoidance behaviors are associated with sleep disturbances in bereavement-related depression. Depress Anxiety 1997; 6: 106–12PubMedCrossRef

42.

Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 2003; 37: 9–15PubMedCrossRef

43.

Pigeon WR, Hegel M, Unutzer J, et al. Is insomnia a perpetuating factor for late-life depression in the IMPACT cohort? Sleep 2008; 31: 481–8PubMed

44.

Ohayon MM. Difficulty in resuming or inability to resume sleep and the links to daytime impairment: definition, prevalence and comorbidity. J Psychiatr Res 2009; 43: 934–40PubMedCrossRef

45.

Ohayon MM. Nocturnal awakenings and comorbid disorders in the American general population. J Psychiatr Res 2008; 43: 48–54PubMedCrossRef

46.

Kennedy GJ, Kelman HR, Thomas C. Persistence and remission of depressive symptoms in late life. Am J Psychiatry 1991; 148: 174–8PubMed

47.

Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60: 221–5PubMedCrossRef

48.

Carney CE, Segal ZV, Edinger JD, et al. A comparison of rates of residual insomnia symptoms following pharma-cotherapy or cognitive-behavioral therapy for major depressive disorder. J Clin Psychiatry 2007; 68: 254–60PubMedCrossRef

49.

Dombrovski AY, Mulsant BH, Houck PR, et al. Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affect Disord 2007; 103: 77–82PubMedCrossRef

50.

Dombrovski AY, Cyranowski JM, Mulsant BH, et al. Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy? Depress Anxiety 2008; 25: 1060–6PubMedCrossRef

51.

Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder [see comment]. Am J Psychiatry 1990; 147: 1189–94PubMed

52.

Paffenbarger RS Jr, Lee IM, Leung R. Physical activity and personal characteristics associated with depression and suicide in American college men. Acta Psychiatr Scand Suppl 1994; 377: 16–22PubMedCrossRef

53.

Agargun MY, Kara H, Solmaz M. Sleep disturbances and suicidal behavior in patients with major depression. J Clin Psychiatry 1997; 58: 249–51PubMedCrossRef

54.

McGirr A, Renaud J, Seguin M, et al. An examination of DSM-IV depressive symptoms and risk for suicide completion in major depressive disorder: a psychological autopsy study. J Affect Disord 2007; 97: 203–9PubMedCrossRef

55.

Carney RM, Freedland KE, Jaffe AS. Insomnia and depression prior to myocardial infarction. Psychosom Med 1990; 52: 603–9PubMed

56.

Riemann D. Insomnia and comorbid psychiatric disorders. Sleep Med 2007; 8 (Suppl. 4): S15–20PubMedCrossRef

57.

Riemann D, Berger M, Voderholzer U. Sleep and depression — results from psychobiological studies: an overview. Biol Psychol 2001; 57: 67–103PubMedCrossRef

58.

Mendlewicz J, Kerkhofs M. Sleep electroencephalography in depressive illness. A collaborative study by the World Health Organization. Br J Psychiatry 1991; 159: 505–9

59.

Friess E, Modell S, Brunner H, et al. The Munich vulnerability study on affective disorders: microstructure of sleep in high-risk subjects. Eur Arch Psychiatry Clin Neurosci 2008; 258: 285–91PubMedCrossRef

60.

Modell S, Ising M, Holsboer F, et al. The Munich vulnerability study on affective disorders: premorbid poly-somnographic profile of affected high-risk probands. Biol Psychiatry 2005; 58: 694–9PubMedCrossRef

61.

Rao U, Hammen CL, Poland RE. Risk Markers for Depression in Adolescents: Sleep and HPA Measures. Neuropsychopharmacology 2009; 34: 1936–45PubMedCrossRef

62.

Kang RH, Choi MJ, Paik JW, et al. Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. Int J Psychiatry Med 2007; 37: 315–29PubMedCrossRef

63.

Cohn JB. Triazolam treatment of insomnia in depressed patients taking tricyclics. J Clin Psychiatry 1983; 44:401–6PubMed

64.

Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999; 60: 668–76PubMedCrossRef

65.

Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006; 59: 1052–60PubMedCrossRef

66.

Krystal A, Fava M, Rubens R, et al. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med 2007; 3: 48–55PubMed

67.

Bertschy G, Ragama-Pardos E, Muscionico M, et al. Trazodone addition for insomnia in venlafaxine-treated, depressed inpatients: a semi-naturalistic study. Pharmacol Res 2005; 51: 79–84PubMedCrossRef

68.

Jacobsen FM. Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. J Clin Psychiatry 1990; 51: 298–302PubMed

69.

Kaynak H, Kaynak D, Gozukirmizi E, et al. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med 2004; 5: 15–20PubMedCrossRef

70.

Nierenberg AA, Keck Jr PE. Management of monoamine oxidase inhibitor-associated insomnia with trazodone. J Clin Psychopharmacol 1989; 9: 42–5PubMedCrossRef

71.

Mashiko H, Niwa S, Kumashiro H, et al. Effect of trazodone in a single dose before bedtime for sleep disorders accompanied by a depressive state: dose-finding study with no concomitant use of hypnotic agent. Psychiatry Clin Neurosci 1999; 53: 193–4PubMedCrossRef

72.

Ware JC, Brown FW, Moorad PJ Jr, et al. Effects on sleep: a double-blind study comparing trimipramine to imipra-mine in depressed insomniac patients. Sleep 1989; 12: 537–49PubMed

73.

Haskell DS, DiMascio A, Prusoff B. Rapidity of symptom reduction in depressions treated with amitriptyline. J Nerv Ment Dis 1975; 160:24–33PubMedCrossRef

74.

Simon GE, Heiligenstein JH, Grothaus L, et al. Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. J Clin Psychiatry 1998; 59: 49–55PubMedCrossRef

75.

Benedetti F, Pontiggia A, Bernasconi A, et al. Lormetazepam in depressive insomnia: new evidence of phase-response effects of benzodiazepines. Int Clin Psychopharmacol 2004; 19: 311–7PubMedCrossRef

76.

Rush AJ, Armitage R, Gillin JC, et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 1998; 44: 3–14PubMedCrossRef

77.

Scharf MB, McDannold M, Zaretsky N, et al. Evaluation of sleep architecture and cyclic alternating pattern rates in depressed insomniac patients treated with nefazodone hydrochloride. Am J Ther 1999; 6: 77–82PubMedCrossRef

78.

Mouret J, Lemoine P, Minuit MP, et al. Effects of trazodone on the sleep of depressed subjects-a polygraphic study. Psychopharmacology (Berl) 1988; 95 (Suppl.): S37–43PubMedCrossRef

79.

Parrino L, Spaggiari MC, Boselli M, et al. Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. Psychopharmacology (Berl) 1994; 116: 389–95CrossRef

80.

Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychophar-macol Biol Psychiatry 2002; 26: 249–60CrossRef

81.

Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry 1990; 51 (Suppl.): 13–17PubMed

82.

Shen J, Chung SA, Kayumov L, et al. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry 2006; 51: 27–34PubMed

83.

Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723–32PubMedCrossRef

84.

Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10: 661–73PubMed

85.

Quera Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007; 10: 691–6PubMed

86.

Armitage R, Yonkers K, Cole D, et al. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol 1997; 17: 161–8PubMedCrossRef

87.

Gillin JC, Rapaport M, Erman MK, et al. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 1997; 58: 185–92PubMedCrossRef

88.

Loo H, Dalery J, Macher JP, et al. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders. Encephale 2002; 28: 356–62PubMed

89.

Loo H, Dalery J, Macher JP, et al. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin-agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders. Encephale 2003; 29: 165–71PubMed

90.

Kuo T, Manber R, Loewy D. Insomniacs with comorbid conditions achieved comparable improvement in a cognitive behavioral group treatment program as insomniacs without comorbid depression. Sleep 2001; 14: A62

91.

Lichstein KL, Wilson NM, Johnson CT. Psychological treatment of secondary insomnia. Psychol Aging 2000; 15: 232–40PubMedCrossRef

92.

Manber R, Edinger JD, Gress JL, et al. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep 2008; 31: 489–95PubMed

93.

Morawetz D. Insomnia and depression: which comes first? Aust J Counselling Psychol 2001; 3: 19–24

94.

Perlis M, Aloia M, Millikan A, et al. Behavioral treatment of insomnia: a clinical case series study. J Behav Med 2000; 23: 149–61PubMedCrossRef

95.

Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy versus zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 2006; 295: 2851–8PubMedCrossRef

96.

Omvik S, Sivertsen B, Pallesen S, et al. Daytime functioning in older patients suffering from chronic insomnia: treatment outcome in a randomized controlled trial comparing CBT with Zopiclone. Behav Res Ther 2008; 46: 623–41PubMedCrossRef

97.

Taylor DJ, Lichstein KL, Weinstock J, et al. A pilot study of cognitive-behavioral therapy of insomnia in people with mild depression. Behav Ther 2007; 38: 49–57PubMedCrossRef

98.

Thase ME, Rush AJ, Manber R, et al. Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. J Clin Psychiatry 2002; 63: 493–500PubMedCrossRef

99.

Lyness JM, Noel TK, Cox C, et al. Screening for depression in elderly primary care patients. A comparison of the Center for Epidemiologic Studies-Depression Scale and the Geriatric Depression Scale. Arch Intern Med 1997; 157:449–54PubMedCrossRef

100.

Morawetz D. Insomnia and depression: which comes first? Sleep Res Online 2003; 5: 77–81

101.

Smith MT, Perlis ML, Park A, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002; 159: 5–11PubMedCrossRef

102.

Carney CE, Edinger JD, Meyer B, et al. Symptom-focused rumination and sleep disturbance. Behav Sleep Med 2006; 4: 228–41PubMedCrossRef

103.

Carlson LE, Garland SN. Impact of mindfulness-based stress reduction (MBSR) on sleep, mood, stress and fatigue symptoms in cancer outpatients. Int J Behav Med 2005; 12: 278–85PubMedCrossRef

104.

Dirksen SR, Epstein DR. Efficacy of an insomnia intervention on fatigue, mood and quality of life in breast cancer survivors. J Adv Nurs 2008; 61: 664–75PubMedCrossRef

105.

Espie CA, Fleming L, Cassidy J, et al. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol 2008; 26: 4651–8PubMedCrossRef

106.

Quesnel C, Savard J, Simard S, et al. Efficacy of cognitive-behavioral therapy for insomnia in women treated for nonmetastatic breast cancer. J Consult Clin Psychol 2003; 71: 189–200PubMedCrossRef

107.

Savard J, Simard S, Ivers H, et al. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: Sleep and psychological effects. J Clin Oncol 2005; 23: 6083–96PubMedCrossRef

108.

Zee PC, Ancoli-Israel S. Does effective management of sleep disorders reduce cancer-related fatigue? Drugs 2009; 69 (suppl 2): 63–75CrossRef

109.

Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005; 66: 469–76PubMedCrossRef

110.

Wiegand MH. Antidepressants for the treatment of insomnia: a suitable approach? Drugs 2008; 68: 2411–7PubMedCrossRef

111.

Landolt HP, Meier V, Burgess HJ, et al. Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 1999; 21: 455–66PubMedCrossRef

112.

Rinaldi-Carmona M, Congy C, Santucci V, et al. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. J Pharmacol Exp Ther 1992; 262: 759–68PubMed

113.

Teegarden BR, Al Shamma H, Xiong Y. 5-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem 2008; 8: 969–76PubMedCrossRef

114.

Rush AJ, First MB, Blacker D. Handbook of psychiatric measures. 2nd ed. Washington, DC: American Psychiatric Publishing, Inc., 2007

115.

Zallek SN, Redenius R, Fisk H, et al. A single question as a sleepiness screening tool. J Clin Sleep Med 2008; 4: 143-8PubMed

Title: Does Effective Management of Sleep Disorders Reduce Depressive Symptoms and the Risk of Depression?
Author: Professor Dieter Riemann
Publication date: 01-12-2009
Publisher: Springer International Publishing
Published in: Drugs / Issue Special Issue 2/2009
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/11531130-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Does Effective Management of Sleep Disorders Reduce Depressive Symptoms and the Risk of Depression?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2009

Do Sleep Disorders and Associated Treatments Impact Glucose Metabolism?

Does Effective Management of Sleep Disorders Improve Pain Symptoms?

Does Effective Management of Sleep Disorders Reduce Substance Dependence?

Does Effective Management of Sleep Disorders Reduce Cancer-Related Fatigue?

Foreword

Can Improving Sleep Influence Sleep-Disordered Breathing?